Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
New cancer gene therapy research from University of Alabama described
July 29th, 2008
According to a study from the United States, "Enhanced production of receptor activator of nuclear factor-kappa B ligand ( RANKL) and its binding to RANK on the osteoclasts have been associated with osteolysis in breast cancer bone metastasis. Osteoprotegerin ( OPG) is a decoy receptor that prevents RANKL-RANK interaction." "This study determined the effects of sustained expression of OPG using a recombinant adeno-associated viral (rAAV) vector in mouse model of osteolytic breast cancer. Bone metastasis was established by intracardiac injection of the human breast cancer cell line MDA-MB435. Following this, mice were administered a one-time intramuscular injection of...
Source: Cancer Weekly (2008-07-29)
|
